<DOC>
	<DOCNO>NCT01791374</DOCNO>
	<brief_summary>This open label phase 1/1b study Rilotumumab Japanese subject advance solid tumor metastatic gastric esphagogastric ( GEJ ) adenocarcinoma .</brief_summary>
	<brief_title>Phase 1/1b Study Rilotumumab Japanese Subjects With Advanced Solid Tumors Advanced Metastatic Gastric GEJ</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Key Japanese subject pathologically confirm unresectable locally advanced metastatic carcinoma refractory standard therapy standard therapy ( Part 1 ) Japanese subject pathologically confirm METpositive ( fulfil MET IHC criterion define validated IVD [ vitro diagnostic ] ) unresectable locally advanced metastatic gastric GEJ adenocarcinoma ( Part 2 ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( 0 1 ) Availability archival tumor tissue ( Part 2 ) Evaluable ( measurable nonmeasurable ) disease RECIST 1.1 criterion Able tolerate infusion take oral medication ( Part 2 ) Key Previous systemic therapy ( include chemotherapy , biologic , immunotherapy , investigational therapy ) locally advanced metstatic gastric GEJ adenocarcinoma ( Part 2 ) Less 6 month elapse completion prior neoadjuvant adjuvant chemotherapy chemotherapy enrollment ( Part 2 ) Squamos cell history ( Part 2 ) Known HER2overexpressing unresectable locally advanced metastatic gastric GEJ adenocarcinoma ( Part 2 ) Resectable disease suitable definitive chemoradiation Subjects persistent gastric outlet obstruction , complete dysphagia dependent upon jejunostomy feeding ( Part 2 ) Known central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Advanced Metastatic Gastric Cancer</keyword>
	<keyword>Advanced Metastatic GEJ</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>